UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 116

Sortiert nach

A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients

Clinical cancer research, 2009-04, Vol.15 (7), p.2497-2506

2009

Link zum Volltext

Verfügbarkeit prüfen

Education Transmission and Network Formation

Journal of labor economics, 2023-01, Vol.41 (1), p.129-173

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Journal of clinical oncology, 2008-04, Vol.26 (11), p.1810-1816

2008

Link zum Volltext

Verfügbarkeit prüfen

Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

Journal of clinical oncology, 2006-01, Vol.24 (1), p.16-24

2006

Link zum Volltext

Verfügbarkeit prüfen

Time‐Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma

CPT: pharmacometrics and systems pharmacology, 2019-06, Vol.8 (6), p.415-427

2019

Link zum Volltext

Verfügbarkeit prüfen

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

Journal of translational medicine, 2007-07, Vol.5 (1), p.32-32, Article 32

2007

Link zum Volltext

Verfügbarkeit prüfen

Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of Sunitinib

Clinical cancer research, 2009-11, Vol.15 (22), p.7045-7052

2009

Link zum Volltext

Verfügbarkeit prüfen

Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure

Clinical cancer research, 2009-09, Vol.15 (18), p.5902-5909

2009

Link zum Volltext

Verfügbarkeit prüfen

A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period

Cancer chemotherapy and pharmacology, 2008-03, Vol.61 (3), p.515-524

2008

Link zum Volltext

Verfügbarkeit prüfen

Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects

Anti-cancer drugs, 2006-03, Vol.17 (3), p.353-358

2006

Link zum Volltext

Verfügbarkeit prüfen

Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species

Cancer chemotherapy and pharmacology, 2009-09, Vol.64 (4), p.691-706

2009

Link zum Volltext

Verfügbarkeit prüfen

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis

Cancer chemotherapy and pharmacology, 2010-07, Vol.66 (2), p.357-371

2010

Link zum Volltext

Verfügbarkeit prüfen

Changing Body Weight–Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial Carcinoma

Clinical pharmacology and therapeutics, 2020-03, Vol.107 (3), p.588-596

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

The Lancet (British edition), 2006-10, Vol.368 (9544), p.1329-1338

2006

Link zum Volltext

Verfügbarkeit prüfen

A phase I, open-label, mass balance study of [14C] dacomitinib (PF-00299804) in healthy male volunteers

Cancer chemotherapy and pharmacology, 2013-08, Vol.72 (2), p.379-385

2013

Link zum Volltext

Verfügbarkeit prüfen

Sunitinib malate for the treatment of solid tumours: a review of current clinical data

Expert opinion on investigational drugs, 2006-05, Vol.15 (5), p.553-561

2006

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of sunitinib malate in subjects with hepatic impairment

Cancer chemotherapy and pharmacology, 2010-09, Vol.66 (4), p.699-707

2010

Link zum Volltext

Verfügbarkeit prüfen

Exposure–response relationships in patients with metastatic renal cell carcinoma receiving sunitinib: maintaining optimum efficacy in clinical practice

Anti-cancer drugs, 2011-06, Vol.22 (5), p.377-383

2011

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and Safety of Sunitinib Malate in Subjects With Impaired Renal Function

Journal of clinical pharmacology, 2010-04, Vol.50 (4), p.472-481

2010

Link zum Volltext

Verfügbarkeit prüfen

Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers

Journal of clinical pharmacology, 2016-02, Vol.56 (2), p.223-230

2016

Link zum Volltext

Verfügbarkeit prüfen

A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers

Journal of clinical pharmacology, 2014-05, Vol.54 (5), p.555-562

2014

Link zum Volltext

Verfügbarkeit prüfen

The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers

Cancer chemotherapy and pharmacology, 2012-04, Vol.69 (4), p.991-997

2012

Link zum Volltext

Verfügbarkeit prüfen

Balance-of-Payments Crises During the Great Recession: Is This Time Different?

Review of international economics, 2012-08, Vol.20 (3), p.517-534

2012

Link zum Volltext

Verfügbarkeit prüfen

Functional characteristics and steroid hormone-mediated regulation of an organic cation transporter in Madin-Darby canine kidney cells

The Journal of pharmacology and experimental therapeutics, 2001-10, Vol.299 (1), p.392

2001

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 116

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(112)
Mit Volltextzugriff
(100)

Publikationsform

Artikel
(115)
Bücher
(1)

Sprache

Englisch
(115)
Japanisch
(13)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(89)
Life Sciences & Biomedicine
(81)
Humans
(64)
Male
(41)
Biological And Medical Sciences
(37)
Female
(36)
Middle Aged
(32)
Adult
(28)
Medical Sciences
(24)
Oncology
(24)
Aged
(22)
Amino Acid Sequence
(22)
Animals
(19)
Biochemistry & Molecular Biology
(18)
Molecular Sequence Data
(18)
Pharmacology & Pharmacy
(18)
Antineoplastic Agents
(17)
Pharmacology. Drug Treatments
(16)
Protein Conformation
(16)
Fundamental And Applied Biological Sciences. Psychology
(13)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients

Education Transmission and Network Formation

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

Time‐Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of Sunitinib

Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure

A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period

Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects

Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis

Changing Body Weight–Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial Carcinoma

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

A phase I, open-label, mass balance study of [14C] dacomitinib (PF-00299804) in healthy male volunteers

Sunitinib malate for the treatment of solid tumours: a review of current clinical data

Pharmacokinetics of sunitinib malate in subjects with hepatic impairment

Exposure–response relationships in patients with metastatic renal cell carcinoma receiving sunitinib: maintaining optimum efficacy in clinical practice

Pharmacokinetics and Safety of Sunitinib Malate in Subjects With Impaired Renal Function

Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers

A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers

The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers

Balance-of-Payments Crises During the Great Recession: Is This Time Different?

Functional characteristics and steroid hormone-mediated regulation of an organic cation transporter in Madin-Darby canine kidney cells

Suchergebnisse filtern